Summary
Mylan Inc. said Thursday it sharply reduced its net loss for the final quarter and all of 2008 by cutting expenses and the continued integration of its $6.8 billion acquisition of Merck's generics business in October 2007.
For the three months ended Dec. 31, the Cecil-based generic drug maker reported a loss of just under $40 million, or 13 cents a share, compared with a loss of nearly $1.4 billion, or $5.04 a share, one year ago.See the full content of this document
Extract
Mylan Moves Sharply Reduce Loss
Revenue increased 4.1 percent to $1.2 billion from $1.15 billion during the fina...
See the full content of this document
Sponsored links
